Michael Boyne

Michael Boyne, PhD is an accomplished scientific professional and unabashed drug developer, having served as a regulator, consultant, and executive in biotech for over 15 years. Currently, Michael is a Co-Founder and Principal of CatalystBio, a Global Life Sciences Advisory Firm dedicated to moving first-in-class, first-in kind technologies off the bench and into the clinic. Prior to founding CatalystBio, he was the VP of Product Development & Analytics at COUR, where he led the growth of a five-person virtual company to a 50-person operating company and built out manufacturing, quality, research & development, program management, and regulatory functions. He also led both internal and external diligence teams. Before joining COUR, he was a Senior Consultant at BioTechLogic, advising pharmaceutical manufacturers on drug development and CMC strategy, including drafting, reviewing, and authoring CTDs for regulatory submissions. Prior to consulting, he was a Research Chemist in the Division of Pharmaceutical Analysis at the US Food and Drug Administration, where he established a laboratory developing on applying modern analytical technologies to evaluate and regulate complex therapeutics (generics, biologics, and NCE’s). Michael has authored ~ 50 peer-reviewed publications and is an internationally recognized speaker on applying modern analytical technologies to drug development. He currently serves on the Executive Advisory Board for Northwestern’s Chemistry of Life Process Institute and is the Treasurer of the Gower Foundation. Michael was a postdoctoral scholar at Washington University Medical School in Saint Louis, where he was an American Cancer Society/Canary Foundation Fellow in Early Detection. Michael has a BA in Chemistry from Northwestern University and a PhD in Chemistry from the University of Illinois Urbana-Champaign.